Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

MorphoSys AG. News release: MorphoSys licensing partner GSK starts phase 2 study with GSK3196165 (MOR103) in hand osteoarthritis. 2016 Apr 18.
U.S. National Institutes of Health. A study to investigate the efficacy and safety of GSK3196165 in inflammatory hand osteoarthritis. NCT02683785. ClinicalTrials.gov. 2016 Apr 28.
U.S. National Institutes of Health. Study to evaluate the efficacy and safety of GSK3196165 plus methotrexate in subjects with active moderate-severe rheumatoid arthritis. NCT02504671. ClinicalTrials.gov. 2016 Jan 14.
Regeneron Pharmaceuticals Inc. News release: Regeneron announces positive topline results from phase 2/3 fasinumab study in patients with osteoarthritis pain. 2016 May 2.

FDA Restricts Fluoroquinolone Use The U.S. Food and Drug Administration (FDA) has twice previously communicated safety information about systemic fluoroquinolones—in August 2013 and July 2008. The safety issues of this medication class described in its latest Drug Safety Communication were also discussed at a November 2015 FDA Advisory Committee meeting.1 The FDA is now advising…

A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…

A recent analysis found that about 10% of RA patients taking tofacitinib do not follow recommended guidelines and more than half stop treatment by one year…

After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee OA will discontinue the use of higher fasinumab doses…

Rheumatology Drug Updates: Labeling for Fluoroquinolones; FDA to Review Benzhydrocodone/Acetaminophen Combination

Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment

Many Patients Discontinue Tofacitinib by Year 1; Fasinumab Promising for Pain

Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk

Related Articles